Pfizer Faces Setbacks with Clinical Trial Failure and CFO Departure
Pfizer's stock has declined over 50% since late 2021 due to poor financial performance. Recent setbacks include a failed phase 3 clinical trial for sigvotatug vedotin, an NSCLC treatment acquired through the $43 billion Seagen buyout in 2023, and the departure of its CFO on June 18.
Topics: NSCLC clinical trial failure Pfizer Seagen acquisition sigvotatug vedotin